<DOC>
	<DOCNO>NCT00537498</DOCNO>
	<brief_summary>The purpose study evaluate whether treatment urokinase ( 500 000 1 000 000 IU ) lead ulcer-healing , low rate major amputation , prolong survival patient diabetic foot syndrome .</brief_summary>
	<brief_title>Urokinase Therapy Diabetic Foot Syndrome</brief_title>
	<detailed_description>Patients diabetic foot ulceration critical limb ischemia high risk major amputation especially limbs revascularized . Urokinase effective improve microcirculation critical limb ischemia lower fibrinogen might improve outcomes . There however data efficacy safety urokinase treatment term survival free major amputation , ulcer heal rate minor major bleed . Therefore trial conducted investigate effect urokinase treatment parameter .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<criteria>angiopathic angioneuropathic diabetic foot lesion critical limb ischemia surgical interventional treatment option feasibility vascular surgery angioplasty prior treatment current ulceration urokinase need dialysis creatinine &gt; 180Âµmol/l kind cerebral event less three month inclusion study proliferative retinopathy ( remediate ) uncontrolled hypertension hemorrhagic diathesis gastrointestinal bleed need oral anticoagulation mental disorder pregnancy participation another study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>urokinase , diabetes , wound healing , major amputation</keyword>
</DOC>